IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
BESTCALL (cefmenoxime), an in ject able third-gen er a tion cephalosporin an ti bi otic, was launched in Ja -
pan by orig i na tor Takeda in 1983. Roche also mar kets it in Ja pan as Bestcall Roche. It is mar keted in
Ger many and Aus tria by Takeda Pharma as Tacef. Han Il is the li censee for South Ko rea. Senju, Grelan
and Kyorin sell oph thal mic versions in Japan.
FAMVIR (famciclovir) is the in ac tive prodrug of penciclovir, which is ef fec tive against her pes sim plex vi -
rus types 1 and 2. Famciclovir was ap proved for her pes zoster (shin gles) in the UK in De cem ber 1993 and
was launched in the UK, its first mar ket, in Jan u ary 1994. Famciclovir has since been mar keted in the USA
(July 1994) and in over 30 other coun tries worldwide.
Li cens ing: In Sep tem ber 2006, TAP re ported that it had signed a co-pro mo tional agree ment with
Novartis (Swit zer land) for famciclovir in the USA. Un der the terms of the agree ment, TAP was re spon si ble
for pro mot ing famciclovir to ob ste tri cians and gy ne col o gists within the USA. Fur ther de tails of the agree -
ment were not dis closed. In May 2008, Takeda and Abbott con cluded their TAP jv with Takeda re ceiv ing
rights to the product.
FIRSTCIN (cefozopran), a semisynthetic, broad-spec trum, parenteral cephalosporin an ti bi otic, was
launched in Ja pan in 1995 by orig i na tor Takeda and li censee Lederle (now part of Wyeth). Firstcin is par -
tic u larly ef fec tive against se vere in fec tions caused by staph y lo cocci and enterococci in
immunocompromised pa tients. It has been ap proved for pe di at ric use and men in gi tis. It will not com pete
against Takeda’s Pansporin as it is rec om mended for in fec tions that do not respond to Pansporin.
Sales/An a lyst Com ment: With sales of Yen6.4 bil lion re ported in fis cal 2007 (end ing March 2008),
Mor gan Stan ley an a lysts (Au gust 2008) fore cast a de cline in sales to Yen6 bil lion by the year to March
2013.
GLOVENIN (im mu no glob u lin base), a polyvalent in tra ve nous im mu no glob u lin used to treat se vere in -
fec tions and im mu no de fi ciency syndromes.
Sales/An a lyst Com ment: With sales of Yen8.8 bil lion re ported in fis cal 2007 (end ing March 2008), up
from Yen8.6 bil lion the pre vi ous year, Mor gan Stan ley an a lysts (Au gust 2008) fore cast a slight de cline in
sales to Yen8.5 bil lion by the year to March 2013.
PANSPORIN (cefotiam), an in ject able cephalosporin an ti bi otic, was first launched by Takeda in Ja pan in
1981. In 1983, Takeda launched Pansporin in the Phil ip pines and Thai land as Ceradolan, then in 1988 it
was launched in Hong Kong, also as Ceradolan.
In Sep tem ber 2008 Takeda filed a suit against Taiyo Yakuhin who man u fac tures Pansporin, de mand ing
dam ages of Yen2.8 bil lion claim ing its qual ity con trol sys tem was de fi cient af ter it failed to re call all vi als
(in which glass was found) from the market.
Li cens ing: Pansporin was li censed to Ciba for world wide mar ket ing. Ciba (now part of Novartis, Swit zer -
land) has launched it in a num ber of coun tries as Halospor, in clud ing Ger many, the Neth er lands and Ma -
lay sia. Li censee Han Il launched it in South Ko rea in 1983. In 1989, it was ap proved for US mar ket ing as
Ceradon, but has never been launched in North Amer ica and Takeda is not de vel op ing the oral form,
Pansporin T (re fer to drug record) in the USA.
Sales/An a lyst Com ment: With re ported sales of Yen8.4 bil lion in fis cal 2007 (end ing March 2008),
Mor gan Stan ley an a lysts (Au gust 2008) fore cast a de cline in sales to Yen7.0 bil lion by the year to March
2013.
PANSPORIN T (cefotiam hexetil), an oral ver sion of the cephem an ti bi otic Pansporin, was launched in
Ja pan in 1990. In 1993, it was launched in France by Takeda as Taketiam in part ner ship with Roussel
Uclaf (now part of sanofi-aventis, France), which launched it as Texodil. Li censee Cheil launched it in
© 2009 IMS Health In cor po rated or its af fil i ates Page 52